Chief executive officer Pascal Soriot also described the data from the AstraZeneca lung cancer drug trial as statistically positive.
The drugmaker’s shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called Tropion-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media today after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further.
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
แหล่ง: staronline - 🏆 4. / 75 อ่านเพิ่มเติม »